Additional Metadata
Persistent URL dx.doi.org/10.1016/S1470-2045(18)30362-0, hdl.handle.net/1765/114110
Journal The Lancet Oncology
Citation
van den Bent, M.J, Klein, M, Smits, M, Reijneveld, J.C, French, P.J, Clement, P, … Idbaih, A. (2018). Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. The Lancet Oncology, 19(9), 1170–1179. doi:10.1016/S1470-2045(18)30362-0